Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | ABL2 | P42684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | PDE9A | O76083 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | CTSE | P14091 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30813465 | 0.92 | RET (0.40) | EPHX2SRCCYP3A4EGFRABL1 | |
| SCHEMBL30813541 | 0.91 | BTK (0.46) | SRCEGFRABL1ABL2PDE9A | |
| SCHEMBL27217779 | 0.90 | EGFR (0.41) | CYP3A4EGFRMAPTCYP2C9PDE9A | |
| SCHEMBL27217837 | 0.90 | EPHX2 (0.43) | EPHX2STSSRCCYP3A4EGFR | |
| SCHEMBL30813648 | 0.90 | EPHX2 (0.43) | EPHX2STSSRCCYP3A4EGFR | |
| SCHEMBL27217619 | 0.88 | SRC (0.49) | EPHX2STSSRCCYP3A4EGFR | |
| SCHEMBL30813369 | 0.88 | SRC (0.49) | EPHX2STSSRCCYP3A4EGFR | |
| SCHEMBL27217855 | 0.86 | CYP1A2 (0.46) | CYP3A4MAPTCYP2C9PDE9AKMT2A | |
| SCHEMBL30813549 | 0.84 | CLK4 (0.48) | SRCCYP3A4EGFRMAPTCYP2C9 | |
| SCHEMBL27217928 | 0.84 | CLK4 (0.48) | SRCCYP3A4EGFRMAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | EPHX2 2120/4885STS 4814/4885SRC 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.